Alivus Life Sciences Ltd vs Sanofi Consumer Healthcare India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 1046 as of 13 Apr 15:30 . The P/E Ratio of Alivus Life Sciences Ltd changed from 13.4 on March 2022 to 0 on December 2024 . This represents a CAGR of -100.00% over 6 yearsThe P/E Ratio of Sanofi Consumer Healthcare India Ltd changed from 62.6 on December 2024 to 62.6 on December 2024 . This represents a CAGR of 0.00% over 1 years The Market Cap of Alivus Life Sciences Ltd changed from ₹ 5624 crore on March 2022 to ₹ 0 crore on December 2024 . This represents a CAGR of -100.00% over 6 yearsThe Market Cap of Sanofi Consumer Healthcare India Ltd changed from ₹ 11347 crore on December 2024 to ₹ 11347 crore on December 2024 . This represents a CAGR of 0.00% over 1 years The revenue of Alivus Life Sciences Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '25 revenue of ₹ 659.63 crore. This represent the decline of -100% The revenue of Sanofi Consumer Healthcare India Ltd for the Jun '26 is ₹ 234.8 crore as compare to the Mar '25 revenue of ₹ 0 crore. This represent the growth of 9.2233718E16% The ebitda of Alivus Life Sciences Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '25 ebitda of ₹ 208.52 crore. This represent the decline of -100% The ebitda of Sanofi Consumer Healthcare India Ltd for the Jun '26 is ₹ 94.4 crore as compare to the Mar '25 ebitda of ₹ 0 crore. This represent the growth of 9.2233718E16% The net profit of Alivus Life Sciences Ltd changed from ₹ 111.48 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Sanofi Consumer Healthcare India Ltd changed from ₹ 62.7 crore to ₹ 67.8 crore over 8 quarters. This represents a CAGR of 3.99% The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 0 % on December 2024 . This represents a CAGR of -100.00% over 6 yearsThe Dividend Payout of Sanofi Consumer Healthcare India Ltd changed from 6.06 % on December 2023 to 69.89 % on December 2024 . This represents a CAGR of 239.60% over 2 years .

About Alivus Life Sciences Ltd

Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune.
Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company.
The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business.

About Sanofi Consumer Healthcare India Ltd

Sanofi Consumer Healthcare India Limited was incorporated on May 10, 2023, as part of Sanofi's global strategy to establish a standalone Consumer Healthcare business.
This strategic move resulted in the demerger of the Consumer Healthcare business from Sanofi India Limited (SIL) into the Company through a Scheme of Arrangement, thereby creating a distinct legal entity.
The Scheme of Arrangement, which was sanctioned by the National Company Law Tribunal, Mumbai (NCLT) enabled the seamless transfer and vesting of all assets, liabilities, and operations of SIL to the Company. Pursuant to the Scheme becoming effective, the Consumer Healthcare Division (CHC) business of Sanofi India Limited (SIL) got demerged into the Company as a going concern through the Scheme of Arrangement and became effective from June 1, 2024.

FAQs for the comparison of Alivus Life Sciences Ltd and Sanofi Consumer Healthcare India Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Sanofi Consumer Healthcare India Ltd?

Market cap of Alivus Life Sciences Ltd is 13,106 Cr while Market cap of Sanofi Consumer Healthcare India Ltd is 10,909 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Sanofi Consumer Healthcare India Ltd?

The stock performance of Alivus Life Sciences Ltd and Sanofi Consumer Healthcare India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Sanofi Consumer Healthcare India Ltd?

As of May 5, 2026, the Alivus Life Sciences Ltd stock price is INR ₹1067.85. On the other hand, Sanofi Consumer Healthcare India Ltd stock price is INR ₹4737.15.

How do dividend payouts of Alivus Life Sciences Ltd and Sanofi Consumer Healthcare India Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Sanofi Consumer Healthcare India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.